Treatment decisions are made by a licensed provider after reviewing each patients medical history
Enrolled patients had a baseline or recent liver biopsy showing clinically significant MASLD (metabolic dysfunction-associated steatotic liver disease), defined as MASH with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) 4 with a score of 1 or more in steatosis, lobular inflammation, and hepatocyte ballooning
References WHO | Cardiovascular diseases (CVDs)
If youre ready to compare GLP-1 telehealth options, our quiz can help Find My GLP-1 References, Methodology, and Update Log How This Guide Was Researched All clinical trial data in this guide comes from one of four source types: Peer-reviewed publications (New England Journal of Medicine, Nature Medicine, JAMA) Official Eli Lilly press releases (via investor.lilly.com and PR Newswire) ClinicalTrials.gov registrations (NCT numbers linked throughout) FDA official communications (warning letters, safety advisories) We do not cite social media posts, unregulated seller claims, anecdotal reports, or promotional materials from non-clinical sources
Retrieved from Compliance code : 52343-X-0625